Exon 20

1 clinical trials · Condition

Record	Firm	Date
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (NCT07128199)	Taiho Oncology, Inc.	2025-12-22

Every clearance here is in the API, with alerts when new ones post.